Primecap Management Co. CA Sells 149,060 Shares of Sanofi $SNY

Primecap Management Co. CA cut its stake in shares of Sanofi (NASDAQ:SNY) by 13.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 986,468 shares of the company’s stock after selling 149,060 shares during the period. Primecap Management Co. CA’s holdings in Sanofi were worth $46,561,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Raymond James Financial Inc. boosted its holdings in shares of Sanofi by 81.3% during the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after acquiring an additional 2,635,867 shares in the last quarter. Franklin Resources Inc. raised its position in Sanofi by 9.9% in the second quarter. Franklin Resources Inc. now owns 4,274,410 shares of the company’s stock valued at $206,497,000 after purchasing an additional 384,902 shares during the last quarter. Mondrian Investment Partners LTD acquired a new stake in shares of Sanofi during the third quarter valued at about $171,742,000. Equity Investment Corp grew its holdings in shares of Sanofi by 3.0% during the third quarter. Equity Investment Corp now owns 2,587,690 shares of the company’s stock worth $122,139,000 after purchasing an additional 75,255 shares during the last quarter. Finally, Brandes Investment Partners LP increased its stake in shares of Sanofi by 9.1% in the second quarter. Brandes Investment Partners LP now owns 2,483,767 shares of the company’s stock valued at $119,992,000 after buying an additional 208,090 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Sanofi Trading Up 1.6%

SNY opened at $48.35 on Friday. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The company has a fifty day moving average of $47.53 and a 200-day moving average of $48.57. The stock has a market cap of $117.93 billion, a PE ratio of 13.43, a price-to-earnings-growth ratio of 1.23 and a beta of 0.45. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Barclays cut shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $62.67.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.